SAMIA ZAHI RACHED
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina
33 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 33
- Comparação entre medidas objetivas do tabagismo e tabagismo autodeclarado em pacientes com asma ou DPOC: será que nossos pacientes dizem a verdade?(2015) STELMACH, Rafael; FERNANDES, Frederico Leon Arrabal; CARVALHO-PINTO, Regina Maria; ATHANAZIO, Rodrigo Abensur; RACHED, Samia Zahi; PRADO, Gustavo Faibischew; CUKIER, AlbertoObjective: Smoking prevalence is frequently estimated on the basis of self-reported smoking status. That can lead to an underestimation of smoking rates. The aim of this study was to evaluate the difference between self-reported smoking status and that determined through the use of objective measures of smoking at a pulmonary outpatient clinic. Methods: This was a cross-sectional study involving 144 individuals: 51 asthma patients, 53 COPD patients, 20 current smokers, and 20 never-smokers. Smoking status was determined on the basis of self-reports obtained in interviews, as well as through tests of exhaled carbon monoxide (eCO) and urinary cotinine. Results: All of the asthma patients and COPD patients declared they were not current smokers. In the COPD and asthma patients, the median urinary cotinine concentration was 167 ng/mL (range, 2-5,348 ng/mL) and 47 ng/mL (range, 5-2,735 ng/mL), respectively (p < 0.0001), whereas the median eCO level was 8 ppm (range, 0-31 ppm) and 5 ppm (range, 2-45 ppm), respectively (p < 0.05). In 40 (38%) of the patients with asthma or COPD (n = 104), there was disagreement between the self-reported smoking status and that determined on the basis of the urinary cotinine concentration, a concentration > 200 ng/mL being considered indicative of current smoking. In 48 (46%) of those 104 patients, the self-reported non-smoking status was refuted by an eCO level > 6 ppm, which is also considered indicative of current smoking. In 30 (29%) of the patients with asthma or COPD, the urinary cotinine concentration and the eCO level both belied the patient claims of not being current smokers. Conclusions: Our findings suggest that high proportions of smoking pulmonary patients with lung disease falsely declare themselves to be nonsmokers. The accurate classification of smoking status is pivotal to the treatment of lung diseases. Objective measures of smoking could be helpful in improving clinical management and counseling.
article 0 Citação(ões) na Scopus Right lung exclusion in massive pulmonary thromboembolism(2015) ATHANAZIO, Rodrigo Abensur; RACHED, Samia Zahi- What is the optimal large airway size reduction value to determine malacia: exploratory bronchoscopic analysis in patients in Mounier-Kuhn syndrome(2021) LIMA, Evelise; GENTA, Pedro Rodrigues; ATHANAZIO, Rodrigo Abensur; RODRIGUES, Ascedio Jose; APARECIDA, Maria; NAKAMURA, Maria Aparecida Miyuki; RACHED, Samia Zahi; COSTA, Eduardo Leite Vieira; STELMACH, Rafael
bookPart DPOC exacerbada(2018) RACHED, Samia Zahi; ALMEIDA, Guilherme Eler de; CARVALHO, Carlos Roberto Ribeiro deconferenceObject Incremental shuttle walking test: A reproducible and valid measure of exercise tolerance in adult subjects with non-cystic fibrosis bronchiectasis (nCF-BCt)(2013) CAMARGO, Anderson Alves de; RACHED, Samia Zahi; ATHANAZIO, Rodrigo Abensur; AMARAL, Tatiane Soares; LANZA, Fernanda de Cordoba; SELMAN, Jessyca Pachi Rodrigues; CUKIER, Alberto; FERNANDES, Frederico Leon Arrabal; CARVALHO, Celso Ricardo Fernandes; STELMACH, Rafael; CORSO, Simone Dal- Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association)(2023) ATHANAZIO, Rodrigo Abensur; TANNI, Suzana Erico; FERREIRA, Juliana; DALCIN, Paulo de Tarso Roth; FUCCIO, Marcelo B. de; ESPOSITO, Concetta; CANAN, Mariane Goncalves Martynychen; COELHO, Liana Sousa; FIRMIDA, Monica de Cassia; ALMEIDA, Marina Buarque de; MAROSTICA, Paulo Jose Cauduro; MONTE, Luciana de Freitas Velloso; SOUZA, Edna Lucia; PINTO, Leonardo Araujo; RACHED, Samia Zahi; OLIVEIRA, Veronica Stasiak Bednarczuk de; RIEDI, Carlos Antonio; SILVA FILHO, Luiz Vicente Ribeiro Ferreira daCystic fibrosis (CF) is a genetic disease that results in dysfunction of the CF transmembrane conductance regulator (CFTR) protein, which is a chloride and bicarbonate channel expressed in the apical portion of epithelial cells of various organs. Dysfunction of that protein results in diverse clinical manifestations, primarily involving the respiratory and gastrointestinal systems, impairing quality of life and reducing life expectancy. Although CF is still an incurable pathology, the therapeutic and prognostic perspectives are now totally different and much more favorable. The purpose of these guidelines is to define evidence- based recommendations regarding the use of pharmacological agents in the treatment of the pulmonary symptoms of CF in Brazil. Questions in the Patients of interest, Intervention to be studied, Comparison of interventions, and Outcome of interest (PICO) format were employed to address aspects related to the use of modulators of this protein (ivacaftor, lumacaftor+ivacaftor, and tezacaftor+ivacaftor), use of dornase alfa, eradication therapy and chronic suppression of Pseudomonas aeruginosa, and eradication of methicillin-resistant Staphylococcus aureus and Burkholderia cepacia complex. To formulate the PICO questions, a group of Brazilian specialists was assembled and a systematic review was carried out on the themes, with meta-analysis when applicable. The results obtained were analyzed in terms of the strength of the evidence compiled, the recommendations being devised by employing the GRADE approach. We believe that these guidelines represent a major advance to be incorporated into the approach to patients with CF, mainly aiming to favor the management of the disease, and could become an auxiliary tool in the definition of public policies related to CF.
- Automated Computed Tomography Lung Densitometry in Bronchiectasis Patients(2022) SAWAMURA, Marcio Valente Yamada; ATHANAZIO, Rodrigo Abensur; NUCCI, Maria Cecilia Nieves Teixeira Maiorano de; RACHED, Samia Zahi; CUKIER, Alberto; STELMACH, Rafael; ASSUNCAO- JR., Antonildes Nascimento; TAKAHASHI, Marcelo Straus; NOMURA, Cesar Higa
conferenceObject Do physically active and not physically active adult subjects with bronchiectasis have different clinical and functional characteristics?(2013) ATHANAZIO, Rodrigo; RACHED, Samia Zahi; CAMARGO, Anderson Alves de; AMARAL, Tatiane Soares; LANZA, Fernanda de Cordoba; SAMPAIO, Luciana Malosa; CUKIER, Alberto; CARVALHO-PINTO, Regina; CARVALHO, Celso Ricardo Fernandes; STELMACH, Rafael; CORSO, Simone Dal- Brazilian consensus on non-cystic fibrosis bronchiectasis(2019) PEREIRA, Monica Corso; ATHANAZIO, Rodrigo Abensur; DALCIN, Paulo de Tarso Roth; FIGUEIREDO, Mara Rubia Fernandes de; GOMES, Mauro; FREITAS, Clarice Guimaraes de; LUDGREN, Fernando; PASCHOAL, Ilma Aparecida; RACHED, Samia Zahi; MAURICI, RosemeriBronchiectasis is a condition that has been increasingly diagnosed by chest HRCT. In the literature, bronchiectasis is divided into bronchiectasis secondary to cystic fibrosis and bronchiectasis not associated with cystic fibrosis, which is termed non-cystic fibrosis bronchiectasis. Many causes can lead to the development of bronchiectasis, and patients usually have chronic airway symptoms, recurrent infections, and CT abnormalities consistent with the condition. The first international guideline on the diagnosis and treatment of non-cystic fibrosis bronchiectasis was published in 2010. In Brazil, this is the first review document aimed at systematizing the knowledge that has been accumulated on the subject to date. Because there is insufficient evidence on which to base recommendations for various treatment topics, here the decision was made to prepare an expert consensus document. The Brazilian Thoracic Association Committee on Respiratory Infections summoned 10 pulmonologists with expertise in bronchiectasis in Brazil to conduct a critical assessment of the available scientific evidence and international guidelines, as well as to identify aspects that are relevant to the understanding of the heterogeneity of bronchiectasis and to its diagnostic and therapeutic management. Five broad topics were established (pathophysiology, diagnosis, monitoring of stable patients, treatment of stable patients, and management of exacerbations). After this subdivision, the topics were distributed among the authors, who conducted a nonsystematic review of the literature, giving priority to major publications in the specific areas, including original articles, review articles, and systematic reviews. The authors reviewed and commented on all topics, producing a single final document that was approved by consensus.
- Erratum to: Effects of periodontal treatment on exacerbation frequency and lung function in patients with chronic periodontitis: study protocol of a 1-year randomized controlled (vol 17, 2017)(2017) ROMERO, Sergio dos Santos; PINTO, Erika Horacio; LONGO, Priscila Larcher; CORSO, Simone Dal; LANZA, Fernanda Cordoba; STELMACH, Rafael; RACHED, Samia Zahi; LINO-DOS-SANTOS-FRANCO, Adriana; MAYER, Marcia Pinto Alves; BUSSADORI, Sandra Kalil; FERNANDES, Kristianne Porta Santos; MESQUITA-FERRARI, Raquel Agnelli; HORLIANA, Anna Carolina Ratto Tempestini